Author:
Xiong Zhaoping,Cheng Ziqiang,Xu Chi,Lin Xinyuan,Liu Xiaohong,Wang Dingyan,Luo Xiaomin,Zhang Yong,Qiao Nan,Zheng Mingyue,Jiang Hualiang
Abstract
AbstractArtificial intelligence (AI) models usually require large amounts of high-quality training data, which is in striking contrast to the situation of small and biased data faced by current drug discovery pipelines. The concept of federated learning has been proposed to utilize distributed data from different sources without leaking sensitive information of these data. This emerging decentralized machine learning paradigm is expected to dramatically improve the success of AI-powered drug discovery. We here simulate the federated learning process with 7 aqueous solubility datasets from different sources, among which there are overlapping molecules with high or low biases in the recorded values. Beyond the benefit of gaining more data, we also demonstrate federated training has a regularization effect making it superior than centralized training on the pooled datasets with high biases. Further, two more cases are studied to test the usability of federated learning in drug discovery. Our work demonstrates the application of federated learning in predicting drug related properties, but also highlights its promising role in addressing the small data and biased data dilemma in drug discovery.
Publisher
Cold Spring Harbor Laboratory
Reference64 articles.
1. AI-powered drug discovery captures pharma interest;Nat. Biotechnol,2017
2. Rethinking drug design in the artificial intelligence era
3. Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
4. Hunter, A. J. , Lee, W. H. & Bountra, C. Open innovation in neuroscience research and drug discovery. Brain Neurosci. Adv. 2, 2398212818799270 (2018).
5. gDrug development and medical writing in the digital world;Med. Writ,2019
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献